<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01274429</url>
  </required_header>
  <id_info>
    <org_study_id>11-2314</org_study_id>
    <nct_id>NCT01274429</nct_id>
  </id_info>
  <brief_title>Peanut Oral Immunotherapy (OIT) - Initial Pilot Study in Adults</brief_title>
  <official_title>Peanut Oral Immunotherapy (OIT) - Initial Pilot Study in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this study is to produce a new treatment that would benefit adult subjects by
      lowering the risk of anaphylactic reactions (desensitization), and changing the
      peanut-specific immune response in subjects who have peanut allergy (tolerance). This project
      is designed to study the innovative idea that oral immunotherapy (OIT), the ingestion of
      small increasing amounts of food allergen, will desensitize subjects with peanut
      hypersensitivity by regulating their mucosal and systemic immune reactivity and cause
      long-term tolerance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this proposal is to produce a new treatment that would benefit subjects who have
      peanut allergy by lowering the risk of anaphylactic reactions (desensitization), and changing
      the peanut-specific immune response in subjects who have peanut allergy (tolerance). This is
      a research study to test stimulation of the immune system to improve peanut allergy. The
      approach the investigators will use for peanut allergy is called desensitization. A person
      becomes desensitized to a food by taking small, increasing amounts of the food to help the
      body become used to the food so that it no longer causes a severe allergic reaction.

      The study also looks at the safety and immune system effects of the investigational study
      product, peanut protein. The word &quot;investigational&quot; means the study product is still being
      tested in research studies and is not approved by the U.S. Food and Drug Administration
      (FDA).

      This project is designed to study if peanut oral immunotherapy (POIT) will desensitize
      subjects with peanut hypersensitivity by regulating their oral and systemic immune reactivity
      and cause long-term tolerance.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Lack of funding
  </why_stopped>
  <start_date>December 2010</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine Whether This Peanut OIT Protocol Lowers Their Risk of Anaphylactic Reactions and Causes Long-term Tolerance.</measure>
    <time_frame>2-3 years</time_frame>
    <description>Assess mg of peanut tolerated on double-blind placebo-controlled food challenge as a measure of desensitization and tolerance</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the Effect That PNOIT Has on the Peanut-specific Cellular and Humoral Response in Peanut-allergic Subjects.</measure>
    <time_frame>2-3 years</time_frame>
    <description>Measure changes over the course of treatment in serum specific IgE and IgG4, skin prick tests, TH1 and TH2 cytokines, and CD4+ CD25+ FoxP3+ regulatory T cells</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Peanut Allergy</condition>
  <arm_group>
    <arm_group_label>Open label peanut flour</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Orally ingested peanut flour administered in gradually increasing doses up to a maximum maintenance dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peanut flour</intervention_name>
    <description>Peanut flour that is ingested daily and administered in gradually increasing amounts up to a maximum maintenance dose.</description>
    <arm_group_label>Open label peanut flour</arm_group_label>
    <other_name>Peanut OIT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 50 years of age of any gender, race, or ethnicity.

          -  Diagnosis of peanut allergy OR convincing clinical history of peanut allergy.

          -  Detectable serum peanut -specific Immune globin E(IgE) level (CAP-FEIA ≥ 0.35 kU/L)
             and a positive skin prick test (SPT) to peanut.

          -  Participant willing to use effective method of contraception if female for the
             duration of the study, not pregnant or lactating, and not planning to become pregnant.

          -  Positive reaction to ≤ 2 gm peanut protein on entry challenge.

        Exclusion Criteria:

          -  History of severe anaphylaxis to peanut per current National Cancer Institute Common
             Toxicity Criteria for Adverse Effects (NCI-CTCAE) allergic reaction toxicity grading.

          -  Known sensitivity or intolerance to Oats.

          -  FEV1 value &lt;80% predicted or any clinical features of moderate or persistent asthma
             per 2007 National Heart Lung and Blood Institute (NHLBI) guidelines.

          -  Exacerbation of asthma in the past year requiring hospitalization or greater than 1
             emergency department (ED) visit for asthma in the past 6 months.

          -  Use Beta-blockers, ACE inhibitors, angiotensin receptor blocker (ARB) , or calcium
             channel blockers, xolair, or immunological treatments.

          -  Uncontrolled hypertension per JNC 7 Guidelines (BP &gt; 145/95 seated readings on each of
             two or more office visits).

          -  Active eosinophilic gastrointestinal disease which could be exacerbated by peanut oral
             immunotherapy.

          -  Chronic diseases such as diabetes, liver, gastrointestinal, kidney, cardiovascular,
             pulmonary disease, blood disorders, or history of ischemic cardiovascular disease, or
             other conditions that in the opinion of the Investigator make the subject unsuitable
             for induction of food allergy reactions.

          -  Unable to speak English.

          -  Inability to discontinue antihistamines prior to food challenges and skin prick tests.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wesley Burks, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2011</study_first_submitted>
  <study_first_submitted_qc>January 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2011</study_first_posted>
  <results_first_submitted>January 21, 2017</results_first_submitted>
  <results_first_submitted_qc>January 21, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 10, 2017</results_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Peanut allergy</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>OIT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peanut Hypersensitivity</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Open Label Peanut Flour</title>
          <description>Orally ingested peanut flour administered in gradually increasing doses up to a maximum maintenance dose.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study closed do to lack of funding</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Open Label Peanut Flour</title>
          <description>Orally ingested peanut flour administered in gradually increasing doses up to a maximum maintenance dose.
Peanut flour: Peanut flour that is ingested daily and administered in gradually increasing amounts up to a maximum maintenance dose.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.5" lower_limit="18.8" upper_limit="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Determine Whether This Peanut OIT Protocol Lowers Their Risk of Anaphylactic Reactions and Causes Long-term Tolerance.</title>
        <description>Assess mg of peanut tolerated on double-blind placebo-controlled food challenge as a measure of desensitization and tolerance</description>
        <time_frame>2-3 years</time_frame>
        <population>No subjects reached the end of study food challenge prior to closure of the study and therefore no data was collected towards this endpoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Peanut Flour</title>
            <description>Orally ingested peanut flour administered in gradually increasing doses up to a maximum maintenance dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Determine Whether This Peanut OIT Protocol Lowers Their Risk of Anaphylactic Reactions and Causes Long-term Tolerance.</title>
          <description>Assess mg of peanut tolerated on double-blind placebo-controlled food challenge as a measure of desensitization and tolerance</description>
          <population>No subjects reached the end of study food challenge prior to closure of the study and therefore no data was collected towards this endpoint.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Determine the Effect That PNOIT Has on the Peanut-specific Cellular and Humoral Response in Peanut-allergic Subjects.</title>
        <description>Measure changes over the course of treatment in serum specific IgE and IgG4, skin prick tests, TH1 and TH2 cytokines, and CD4+ CD25+ FoxP3+ regulatory T cells</description>
        <time_frame>2-3 years</time_frame>
        <population>No subjects reached the end of study prior to closure of the study and therefore no end of treatment mechanistic data was collected in order to compare against the baseline.</population>
        <group_list>
          <group group_id="O1">
            <title>Open Label Peanut Flour</title>
            <description>Orally ingested peanut flour administered in gradually increasing doses up to a maximum maintenance dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Determine the Effect That PNOIT Has on the Peanut-specific Cellular and Humoral Response in Peanut-allergic Subjects.</title>
          <description>Measure changes over the course of treatment in serum specific IgE and IgG4, skin prick tests, TH1 and TH2 cytokines, and CD4+ CD25+ FoxP3+ regulatory T cells</description>
          <population>No subjects reached the end of study prior to closure of the study and therefore no end of treatment mechanistic data was collected in order to compare against the baseline.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2.5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Open Label Peanut Flour</title>
          <description>Orally ingested peanut flour administered in gradually increasing doses up to a maximum maintenance dose.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye itch</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Eye tearing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinorrhea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Oropharyngeal itching</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Sneezing</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nose itch</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythematous rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Skin itch</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Lip or eye swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Hives</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due to lack of funding prior to any subjects reaching the primary endpoint.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Edwin Kim, Director of the UNC Food Allergy Initiative</name_or_title>
      <organization>University of North Carolina at Chapel Hill</organization>
      <phone>919-843-9087</phone>
      <email>edwinkim@email.unc.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

